Investigation of protein aggregation dynamics with a Bloch surface wave sensor by Paeder, Vincent et al.
Investigation of protein aggregation dynamics with a Bloch surface 
wave sensor
Vincent Paeder*, Sara Santi, Valeria Musi, Hans Peter Herzig
Ecole Polytechnique Fédérale de Lausanne (EPFL), Institute of Microengineering (IMT), Optics and 
Photonics Technology Laboratory (OPT), Neuchâtel, Switzerland
ABSTRACT  
We present a study of the dynamics of protein aggregation using a common path heterodyne Bloch surface wave sensing  
scheme. We demonstrate the ability to detect, during thermal incubation, the early events linked to the aggregation of  
proteins related to conformational diseases. Alzheimer's amyloid-β 1-42 is used to demonstrate the efficiency of the 
method.  A model  based  on  elementary  interactions  is  shown  to  describe  accurately  the  aggregation  process.  The  
described sensing scheme is sensitive to the early events of the aggregation process. is hence proposed as a method for 
the detection of early stages of the evolution of conformational diseases.
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1. INTRODUCTION 
A recent  challenge  for  biophotonics  techniques,  already commonly used in  sensing applications,  is  to  develop  and 
implement new diagnostic tools in different diseases and clinical settings. Here, we propose a new label-free optical 
platform based on Bloch Surface Waves1 (BSW) sensitive to optical variations caused by conformational changes in 
proteins. In particular, this innovative and robust technology is applied to a topic that has become increasingly relevant in  
biomedical  research:  the  early  diagnosis  of  aberrant  degenerative  pathologies  that  are  caused  by  the  formation  of 
amyloid  fibrils  (protein  aggregates).  An  increasing  number  of  pathologies  (degenerative  diseases)  result  from  an 
incorrect protein folding (misfolding) associated with the formation of aggregates (amyloid fibrils2,3). Disorders such as 
Alzheimer and Parkinson diseases, Huntington’s chorea, Creutzfeldt-Jacob disease, cystic fibrosis, Gaucher's disease, 
type II  diabetes mellitus and the wide group of systemic amyloidosis are associated with aggregation of misfolded  
polypeptide chains which are toxic to the cell4. Amyloid fibrils, particularly in their prefibrillar forms (precursors), can 
be highly toxic to cells, suggesting that pre-amyloid oligomeric structures, play a key role in disease pathogenesis5,6. 
It remains essential to develop new tools allowing early detection of the aggregates, since small oligomeric forms of  
aggregates are emerging as being the toxic species, suggesting their key role in disease pathogenesis2. It is imperative 
that new forms of diagnostics be developed to detect the disease prior to the onset of clinical symptoms. This will offer  
patients the prospect of preventive treatments that can block or significantly curb disease progression.
Amyloid fibrils are defined as fibrillar polypeptide aggregates with β-sheet secondary structure7. For many years the only 
structural  information  about  amyloid  ﬁbrils  came  from  imaging  techniques  (TEM,  AFM)  and  from  X-ray  ﬁber  
diffraction. A range of experiments, indicates that the fibrils have extensive β-sheet character, and that these sheets run 
perpendicular to the fibril axis to generate what is described as a cross-β structure8 (Fig. 1). Understanding why and how 
proteins may adopt a non-native fold is essential for designing therapeutic approaches9.
Alzheimer’s  disease (AD) is the most common neurodegenerative  disorder  and a major  health concern  to  societies  
worldwide.  Recent  research  progress  has  given  detailed  knowledge  on  the  molecular  pathogenesis  of  Alzheimer's 
disease. AD is associated with senile plaques of extracellular amyloid-β protein (Aβ)11,12 and neurofibrillar tangles of 
filamentous aggregates  of  abnormally  phosphorylated  and abnormally  β-folded tau protein13,14.  AD is  caused  by an 
enzymatic  cleavage  of  the  amyloid  precursor  protein  (APP),  a  normal  constituent  of  neuronal  cells  thought  to  be 
important for the neuronal development and function. APP releases a mixture of  Aβ peptides, the longest ones being 
Aβ(1-40) and  Aβ(1-42),  which are all highly fibrillogenic12.  A crucial issue in understanding the molecular bases of this 
disease is the identification of the toxic species. 
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Figure  1.  a)  Schematic  description of  the process  of  amyloid formation2 of  a  full  length  initially  folded  protein.  The 
mechanism by which the different proteins gain a conformation, allowing monomers to bind to each other to form the  
regular amyloid fibril, is under intensive investigation. b) A molecular model of an amyloid ﬁbril. This model is derived  
from cryo-EM analysis of ﬁbrils and illustrates the polypeptide chain involved in b-sheet conformation10.
Currently, no definitive diagnostic test for AD exists. The presence of neurofibrillary tangles and amyloid deposits are  
still the disease-defining parameters. Increasing evidence suggests that toxicity is associated with the so-called “soluble  
toxic oligomers”  15-17 rather than to the final mature fibers. Much interest has therefore been paid for the study of the  
oligomers both in Aβ peptides and tau proteins, directly linked to pathologies18 in order to identify reliable biomarkers 
for  AD that  are  suitable  for  minimal  invasive  early  diagnosis  and  prognosis  of  AD.  Exploring  the  molecular  and  
pathological basis of AD can illuminate aspects of the underlying disease mechanism and provides unique opportunities 
to  gain insights  into the  cascade  of  pathological  events  and how they  relate  to  clinical  manifestations.  In  order  to 
significantly tackle the most catastrophic and devastating symptom of Alzheimer's dementia, we must be able to detect 
the disease prior to the onset of clinical symptoms, and be able to offer patients preventative treatments that block or 
significantly slow disease progression19. In vitro studies on these aggregates should provide a description of the fibril 
formation mechanism at the very early stages of aggregation20. 
Here, we briefly describe the  recent results obtained on the conformational analysis and aggregation kinetics study of 
Aβ(1-42) peptides, the first protein system used for our experiments.  The peptide aggregation during thermal incubation 
(pH 7, 37 °C) has been monitored using several well-established techniques available in the laboratory (size exclusion 
chromatography,  UV-visible,  fluorescence and FTIR spectroscopies).  The calibration of the biosensor is  made using 
lysozyme protein, responsible for the hereditary non-neuropathic systemic amyloidosis. This protein has known structure 
and folding properties, it has been well characterized and shown to be useful as model system to examine structural and  
mechanistic principles. Conclusions drawn on these molecules could therefore be confidently generalized to all amyloid 
fibrils. 
2. EXPERIMENTAL METHOD
The applied detection scheme is based on a common path heterodyne interferometer including a BSW sensor 21 (Fig. 2). 
TE and TM polarizations are separated after the sensor and used as reference and object channels, respectively. Such a  
configuration is allowed by the polarization-sensitive characteristics of the BSW, providing a high stability and a high 
sensitivity. The sensor is mounted on a rotating stage to track the resonance frequency of the BSW over large dynamic  
ranges.
BSW are surface waves supported at the surface of truncated periodic structures. A surface mode with a propagation 
constant below the light line in the external medium can be supported provided that a forbidden band exists in the 
underlying  structure.  Forbidden  bands  are  well-known  features  of  periodic  structures.  Therefore,  a  BSW  can  be 
supported by 
Figure 2. Principle of the common path heterodyne BSW sensing scheme
For the sake of convenience and simplicity, the structure used here is a 1D dielectric multilayer stack made of SiO2 
(refractive index nL=1.46) and Si3N4  (refractive index nH=1.95), and grown by PECVD (Oxford Plasmalab 80+). The 
designed stack supports a surface mode in TM polarization in an aqueous environment (n=1.333). 
The BSW is excited in a Kretschmann configuration (Fig. 3). The configuration used in our experiment corresponds to  
case a) (vertical configuration). This choice of configuration allows to discriminate the aggregation process from the  
interaction  of  proteins  with  the  sensor  surface.  It  is  however  less  sensitive  to  the  precipitation  of  aggregates  than  
configuration b). The best configuration depends on the complexity of the aggregation process and of the affinity of the 
sensor surface to proteins in one or several states of aggregation.
Figure 3. Principle of excitation of a BSW in Kretschmann configuration showing two modes of operation: a) vertical  
configuration;  the  aggregates  precipitate,  causing  a  concentration  depletion  near  the  sensor  surface,  and  b) 
horizontal configuration; the aggregates precipitate on the surface, causing a local concentration increase.
A temperature controlled microfluidic chamber is mounted atop the multilayer to incubate small amounts of solution.  
The microfluidic chamber is made of an UV curable polymer (Norland Adhesives NOA-61) replicated with a PDMS  
stamp from a microstructure fabricated in SU-8. Mechanically roughened teflon connectors are attached to the input and  
output  channels  with a  flexible UV curable  polymer (Norland Adhesive  NOA-68).  During incubation,  to avoid the 
evaporation of the fluid, the input and output connectors are sealed with paraffin.
The sensor is mounted in a θ-2θ configuration on rotating stages. The resonance angle corresponds to a sharp dip in the 
reflection spectrum. The evolution of the aggregation process is recorded over time by monitoring the position of the 
reflectivity minimum. Additionally, the phase of the reflected beam is obtained thanks to the heterodyne setup. Near  
resonance, the phase variations are much larger than the intensity variations. The phase signal enables hence to improve  
the sensitivity of the sensing scheme.
3. PREPARATION AND CHARACTERISATION OF PROTEIN SAMPLES
The purification  of  Aβ(1-42)  samples has  been carried out by size exclusion chromatography (SEC), following the 
protocol as developed by A. Jan and H. Lashuel23,24. The Aβ monomeric samples were purified and separated from the 
oligomeric species by choosing specific buffer conditions (Fig. 2a). The conformational characterization of monomeric 
or aggregated forms and the determination of the content of β-sheet secondary structure during the incubation have been 
carried out using FTIR spectroscopy measurements (Fig. 2b). During the last years the use of Fourier transform infrared  
(FTIR) spectroscopy has dramatically expanded and become crucial for monitoring the structure of proteins and to detect 
the presence of  β-sheet secondary structure.  Typically,  the sample is examined before and after  aggregation and an  
increase in β-sheet secondary structure is observed upon amyloid ﬁbril formation25-27. 
Moreover,  the  kinetics  of  aggregation have  been  monitored  by UV-visible  spectroscopy (Fig.  2c)  and  fluorescence 
spectroscopy by the Thioﬂavin T (ThT) colorimetric assay (Fig. 2d). The monomeric samples were incubated under  
specific conditions (pH, temperature, and ionic strength) responsible for oligomer and ﬁbril formation. The results were  
then compared with the BSW based biosensor analysis of the samples incubated under the same conditions.
Figure 4. Biochemical and biophysical characterization of the Aβ(1-42) peptide. (a) Size exclusion chromatography. The samples 
Aβ(1-42) are purified to monomer conformation by size exclusion chromatography in different buffer composition. In 
blue and black line runs of Aβ with elution buffer 10mM Tris HCl at different concentration (Vr Aβ (1-42) oligomer 8.15 
mL; Vr Aβ(1-42) monomer 12.53 mL); in red line running of Aβ with elution buffer 10mM Tris HCl and 70mM NaCl  
(Vr Aβ(1-42) oligomer 9.4 mL; Vr Aβ(1-42) monomer 14.5 mL). (b) FTIR spectroscopy. Amide I band region in the FTIR 
spectrum of Aβ peptide. Solid lines: IR spectra of the Aβ (1-42) peptide during the incubation in D2O. Dotted line: the IR 
spectrum  of  a  monomer  obtained  in  different  buffer  conditions  (30%  v/v  HFIP,  70%  v/v  D2O).  (c)  UV-vis  
spectroscopy. Time-dependent absorbance of incubated Aβ (1-42) sample monitored at 250 nm (black line). Red line: 
fitting  curve  obtained  applying  the  nucleation-elongation  kinetic  model28.  (d)  Fluorescence.  Time-dependent 
aggregation  of  Aβ(1-42) monitored  by  the  fluorescence  change  of  Thioflavin-T at  482  nm.  Open circles  represent 
fluorescence data, the continuous black line is the curve obtained by fitting the experimental data with the equation 
describing the nucleation-elongation kinetic model28.
The dominant contribution to the BSW sensor signal comes from density changes near the sensor surface. Such density  
changes happen in various situations, such as:
– proteins are adsorbed on the surface, causing a concentration increase
– aggregates grow in immediate proximity to the surface, causing a concentration increase
– aggregates precipitate away from the surface, causing a concentration decrease
Based on these considerations, an aggregation model based on elementary interactions has been derived (Fig. 5). The 
protein-protein interactions are taken form the model proposed in ref. 28. The interactions with the sensor surface depend  
on the hydrophobicity of the surface22.
Three different concentrations of Aβ(1-42) have been investigated. The sensor response in the three cases is shown in Fig.  
6. The model corresponding to the assumptions proposed above is seen to be in very good agreement. According to these 
assumptions, a strong signal is observed in the early stages of the aggregation process. The BSW sensing scheme is  
hence proposed as a tool to detect the aggregation of proteins at early stages.
4. CONCLUSIONS
We show in this study that  a BSW-based heterodyne sensing scheme is suitable to investigate the dynamics of the 
aggregation processes of proteins. Measurements on Alzheimer's beta amyloids show that the detection process relies on  
adsorption of monomers and small aggregates, as well as density depletion due to precipitation of large aggregates. A 
model based on elementary interactions is proposed. This model is in excellent agreement with the measured data. The 
ability of the BSW sensing principle is demonstrated to detect the conformational changes of aggregating proteins in a  
label-free way.These results are of prime interest for the detection of conformational diseases at an early stage.
Figure  5.  elementary  interactions  taken  into  account  in  the  measurement  model 
proposed here. The process of protein aggregation is modeled as a two-step 
process  (left  side)28  A:  monomeric  proteins,  B:  aggregated  proteins.  The 
interaction  with  the  sensor  surface  (right  side)  is  proposed  from  the 
hydrophobic  nature  of  unfolded  proteins.  The  insoluble  aggregates  are 
assumed to precipitate away from the sensor surface.
     
Figure 6. Recorded evolution of the reflectivity minimum for three protein concentrations. a) 45 μM, b) 22 μM and c) 
14 μM. The blue curve corresponds to the measured data and the red curve represents the fitted model.
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